Crispr Therapeutics shares tumble after significant earnings miss
In a challenging market environment, ePlus Inc . (NASDAQ:PLUS) stock has recorded a new 52-week low, dipping to $67.67, with technical indicators from InvestingPro suggesting the stock is in oversold territory. The company maintains strong financial health with a GOOD rating and holds more cash than debt on its balance sheet. This latest price level reflects a notable downturn for the company, with a steep 14.7% decline just in the past week and a 19.7% drop over the last six months. Investors are closely monitoring ePlus as it navigates through the current economic headwinds, assessing the company’s performance and potential strategies to rebound from this low point. The 52-week low serves as a critical indicator for market watchers and shareholders, marking the lowest price at which the stock has traded during the last year and setting a new benchmark for the company’s valuation. Despite recent challenges, the company maintains healthy profitability with a 25.2% gross margin and strong liquidity ratios. Get access to 8 more exclusive InvestingPro Tips and comprehensive analysis in our Pro Research Report.
In other recent news, ePlus revealed its Q4 2024 financial results, missing both earnings and revenue forecasts. The company reported an earnings per share (EPS) of $1.06, falling short of the expected $1.46. Revenue also failed to meet expectations, reaching only $511 million against a forecast of $566.3 million. Despite these disappointing figures, ePlus saw significant growth in services revenue, which increased by 52% year-over-year. Additionally, ePlus launched new AI programs, showcasing innovation in their product lineup. The company’s performance in Q4 2024 showed mixed results, with a slight increase in consolidated net sales to $511 million, but a failure to meet the revenue forecast. Looking ahead, ePlus projects fiscal 2025 revenue between $2.070 billion and $2.110 billion, with adjusted EBITDA forecasted at $165 million to $171 million.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.